Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncology Groups Ask HHS To Revise How Sequester’s Cuts Are Applied To Part B Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

A 2% cut is being applied first to the average sales price for drugs reimbursed by Medicare Part B, and then another 2% is taken out of the 6% add-on. The approach compounds the overall reduction to a level that far exceeds the 2% Medicare cut required by sequestration, according to the groups.

You may also be interested in...



Cancer Drug Access Unaffected By Medicare Sequester, CMS’ Blum Says

Fears that sequestration cuts to Medicare Part B drug payments would lead to drug access issues have failed to materialize, CMS’ Jonathan Blum tells the FDA/CMS Summit.

CMS Lacks Authority To Exempt Part B Drugs From Sequester Cuts – Tavenner

“We do not believe that we have the authority under the Budget Control Act of 2011 to exempt Medicare payment for Part B drugs,” CMS Administrator Marilyn Tavenner told members of Congress in a June 3 letter.

Sequester May Further Depress AmerisourceBergen’s Oncology Drug Sales

Wholesalers AmerisourceBergen and McKesson discuss the potential impact of the federal budget sequester and the resulting cut to Part B drug reimbursement on oncology drug sales.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel